By Counterforce Health Team in Keytruda (pembrolizumab) —

How to Get Keytruda (pembrolizumab) Covered by Aetna in Illinois: Complete Coverage Guide with Appeals Process

Answer Box: Getting Keytruda Covered by Aetna in Illinois

Fastest path to approval: Aetna requires precertification for Keytruda with specific biomarker documentation (PD-L1 CPS, MSI-H, or TMB-H depending on cancer type). Submit the Aetna precertification form with complete clinical notes, pathology reports, and prior treatment history. If denied, Illinois offers automatic external review with binding decisions. First step today: Verify your biomarker testing meets Aetna's specific thresholds and gather all required documentation before submitting.

Table of Contents

Aetna's Coverage Policy Overview

Aetna considers Keytruda (pembrolizumab) medically necessary for multiple cancer types when specific criteria are met. The insurer requires precertification for all plan types—commercial, Medicare Advantage, and Medicaid managed care plans.

Key Policy Points:

  • All Keytruda administrations require prior authorization through CVS Specialty or medical benefit precertification
  • Coverage follows FDA-approved indications and recognized compendia for off-label use
  • Biomarker testing documentation is mandatory for most indications
  • Site of care utilization management applies to infusion administration
Note: Aetna's Clinical Policy Bulletin 0890 provides the complete coverage criteria and is updated regularly as new FDA approvals are granted.

Biomarker and Indication Requirements

Aetna's coverage depends heavily on biomarker status, which varies by cancer type. Missing or inadequate biomarker documentation is the leading cause of denials.

Coverage at a Glance

Cancer Type Required Biomarker Threshold FDA-Approved Test Required
Cervical cancer PD-L1 CPS ≥1 Yes
Gastric/GEJ/Esophageal PD-L1 CPS (HER2-negative) ≥1 or ≥10 Yes
Ampullary adenocarcinoma MSI-H, dMMR, or TMB-H MSI-H/dMMR or TMB ≥10 mut/Mb Yes
Anal carcinoma None for subsequent lines N/A N/A
Multiple solid tumors MSI-H/dMMR or TMB-H As specified Yes

Critical Documentation Requirements:

  • Biomarker testing must use FDA-approved companion diagnostics
  • Results must clearly state the numerical score (e.g., "CPS = 15" not "CPS positive")
  • Testing should be performed on the most recent tumor sample when possible
  • Include the laboratory report with the precertification submission
Tip: Order comprehensive biomarker testing early in the diagnostic process. Counterforce Health helps clinicians identify which specific biomarkers Aetna requires for each indication and ensures proper documentation formatting.

Step Therapy and Medical Exceptions

Aetna may require patients to try other treatments before approving Keytruda, depending on the cancer type and line of therapy.

Common Step Therapy Requirements:

  • First-line therapy: May require chemotherapy failure for some indications
  • PD-1/PD-L1 progression: Generally excludes coverage except for specific melanoma scenarios
  • Combination therapy: Each component drug may have separate step therapy requirements

Medical Exception Pathways:

  1. Contraindication to required therapy: Document specific medical reasons why standard treatments cannot be used
  2. Previous treatment failure: Provide detailed records of prior therapy attempts and outcomes
  3. Intolerance: Include adverse event documentation and severity assessment

Exception Documentation Must Include:

  • Specific contraindications with supporting clinical rationale
  • Previous treatment history with dates, dosages, and outcomes
  • Laboratory values or imaging showing treatment failure
  • Physician attestation of medical necessity

Site of Care and Administration Requirements

Aetna applies site of care utilization management to Keytruda infusions, potentially limiting where treatment can be administered.

Approved Administration Sites:

  • Hospital outpatient departments
  • Ambulatory infusion centers
  • Qualified physician offices
  • Home infusion (may require additional approval)

Administration Requirements:

  • Intravenous infusion only (subcutaneous formulation if FDA-approved)
  • Qualified healthcare professional supervision required
  • Emergency management capabilities must be available
  • Proper infusion protocols and monitoring
Important: Verify your chosen infusion site meets Aetna's network and site of care requirements before scheduling. Contact Aetna at 1-866-752-7021 to confirm site eligibility.

Required Documentation Checklist

For Initial Prior Authorization:

  • Completed Aetna Keytruda precertification form
  • Pathology report with cancer diagnosis and staging
  • Biomarker testing results (PD-L1, MSI-H/dMMR, TMB-H as applicable)
  • Complete treatment history including prior therapies and outcomes
  • Current imaging studies showing disease status
  • Laboratory values (CBC, comprehensive metabolic panel, liver function)
  • Physician attestation of medical necessity

For Appeals:

  • Original denial letter from Aetna
  • Updated clinical notes documenting current status
  • Additional supporting literature or guidelines
  • Peer-to-peer review notes (if conducted)
  • Patient impact statement (optional but helpful)

Appeals Process in Illinois

Illinois provides robust patient protection for insurance denials, with automatic external review for medical necessity denials starting in 2025.

Step-by-Step Appeals Process:

  1. Internal Appeal (Required First Step)
    • Timeline: Submit within 180 days of denial
    • Method: Use Aetna Provider Appeal Form or member appeal form
    • Response Time: 45 business days for standard, 24-72 hours for expedited
  2. Automatic External Review (New in 2025)
    • Trigger: All medical necessity denials automatically forwarded unless patient opts out
    • Reviewer: Independent physician with relevant specialty expertise
    • Decision: Binding on Aetna
    • Cost: Free to patient
  3. Illinois Department of Insurance External Review
    • Timeline: File within 4 months of final denial
    • Form: Request for External Review
    • Contact: Illinois DOI at 877-527-9431
    • Decision Timeline: 5 business days after all materials received

Clinician Corner: Medical Necessity Letter

When appealing to Aetna, your medical necessity letter should include:

Essential Elements:

  • Patient's specific cancer diagnosis with ICD-10 code
  • Disease stage and progression status
  • Biomarker results supporting Keytruda use
  • Previous treatments attempted and outcomes
  • Clinical rationale for Keytruda necessity
  • Reference to NCCN Guidelines or other recognized standards
  • Urgency factors if applicable

Template Opening: "I am writing to appeal the denial of Keytruda (pembrolizumab) for [Patient Name], who has [specific cancer diagnosis] with [relevant biomarker status]. Based on [specific clinical factors], Keytruda is medically necessary and represents the standard of care as outlined in current NCCN Guidelines."

Common Denial Reasons and Solutions

Denial Reason Solution Required Documentation
Missing biomarker data Submit FDA-approved test results Laboratory report with specific scores
Wrong line of therapy Document prior treatment failure Treatment history with dates and outcomes
Experimental/investigational Cite FDA approval and guidelines FDA label, NCCN reference
Site of care restriction Request medical exception Clinical justification for specific site
Quantity/frequency limits Provide dosing rationale Weight-based calculations, FDA dosing
From our advocates: "We've seen Aetna reverse denials when appeals include the exact biomarker thresholds from their policy bulletin. Many initial denials stem from incomplete biomarker reporting rather than clinical inappropriateness. Always cross-reference your test results against Aetna's specific requirements before submitting."

Cost and Financial Assistance

Keytruda costs approximately $23,591 per 6-week dose, making financial assistance crucial for many patients.

Available Support Programs:

  • Merck Access Program: Copay assistance and patient support
  • State pharmaceutical assistance programs in Illinois
  • Cancer-specific foundations and grants
  • Hospital charity care programs

Insurance Coverage Tips:

  • Verify your plan's specialty drug tier and coinsurance
  • Check if CVS Specialty is required for dispensing
  • Understand your annual out-of-pocket maximum
  • Consider supplemental insurance if available

When Treatment Can't Wait

For urgent situations where delays could jeopardize health:

  1. Request expedited review from Aetna (24-72 hour response)
  2. File expedited external review with Illinois DOI
  3. Contact Illinois Attorney General Health Care Helpline: 1-877-305-5145
  4. Consider emergency/compassionate use through Merck

Counterforce Health specializes in urgent appeals and can help expedite the documentation process when time is critical.

FAQ

How long does Aetna prior authorization take for Keytruda in Illinois? Standard precertification decisions take 30-45 days, while expedited requests for urgent cases are decided within 24-72 hours. Submit complete documentation to avoid delays.

What if Keytruda is non-formulary on my Aetna plan? Request a formulary exception by demonstrating medical necessity and providing clinical justification. Include documentation that preferred alternatives are inappropriate or have failed.

Can I appeal if I live in Illinois but have coverage from another state? Yes, Illinois external review rights apply to Illinois residents regardless of where their insurance plan is based, as long as the plan is regulated by Illinois.

Does step therapy apply if I've already failed treatments outside Illinois? Previous treatment failures from any location count toward step therapy requirements. Provide complete documentation of prior therapies and outcomes.

How much will Keytruda cost with Aetna coverage? Costs vary by plan design. Most members pay coinsurance (typically 10-40% for specialty drugs) plus any applicable deductible. Check your specific plan documents for exact costs.

What happens if the external review decision favors coverage? External review decisions are binding on Aetna. The insurer must provide coverage and cannot appeal the decision. Treatment can typically begin within days of a favorable ruling.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage decisions depend on individual plan terms and clinical circumstances. Always consult with your healthcare provider and insurance plan directly for coverage determination. For assistance with complex appeals, contact the Illinois Department of Insurance at 877-527-9431 or the Illinois Attorney General's Health Care Helpline at 1-877-305-5145.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.